Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock
Key stats
- Market cap
- $1.84B
- Price / Earnings ratio
- -28.3x
- EPS (TTM)
- -$67.56
- Volume
- Loading
- 52-week high
- $55.42
- 52-week low
- $23.00
Source: third-party data provider, as of November 13, 2026
Compare with COAG
Technical indicators
- RSI 14
- 50.75
- MACD 12/26/9
- 1.97
- EMA 9 of MACD
- 1.75
- MACD histogram
- 0.21
- SMA 50
- $37.23
- Price above SMA 50
- EMA 50
- $38.57
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
About Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. The company aims to advance treatment approaches for bleeding and thrombotic diseases through the discovery, development, and potential commercialization of innovative therapeutics. Its strategy is centered on addressing significant unmet medical needs among patients globally who are affected by serious coagulation-related conditions
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Benny Sorensen M.D., Ph.D. | President, CEO & Director | 1974 |
| Mr. Mads Nikolaj Behrndt-Eriksen M.Sc. | CFO & GM | 1983 |
| Dr. Ananthram Sreenivasa Murthy M.Sc., Ph.D. | Chief Operating Officer | 1978 |
| Dr. Catherine Eilleen Madigan M.D. | Chief Medical Officer | 1972 |
| Ms. Karen Weisbach | Chief People & Culture Officer | — |
| Ms. Cecile Bonvoisin M.Sc. | Senior Vice President of CMC & Manufacturing | — |
| Ms. Tara O'Meara | Senior Vice President of Development Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.75
- MACD 12/26/9
- 1.97
- EMA 9 of MACD
- 1.75
- MACD histogram
- 0.21
- SMA 50
- $37.23
- Price above SMA 50
- EMA 50
- $38.57
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $56.00
- Average
- $63.00
- High
- $70.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.2 | +35.4 | +46.3 | +1.6 | -29.9 | +33.5 | -4.5 |




